CJC-1295 / Ipamorelin Dosage: Reported Research Ranges
Reported in research: ipamorelin 100–300 mcg daily and CJC-1295 (no DAC) 100–300 mcg daily in practitioner protocols; CJC-1295 with DAC is listed at 300–1,000 mcg twice weekly or 2 mg weekly. No human-trial dose for the pair is reported in our study library. Sources vary.
Dosing Protocols Research · Peptide dosage chart · What is CJC-1295 / Ipamorelin? · Research library
Reported ranges by source
| Reported range | Source type | Evidence strength |
|---|---|---|
| Ipamorelin: 100–300 mcg once daily (one source lists 5 days on, 2 days off) | Practitioner protocols | Practitioner protocol (not a clinical trial) |
| CJC-1295 (no DAC): 100–300 mcg once daily | Practitioner protocols | Practitioner protocol (not a clinical trial) |
| CJC-1295 (DAC): 300–1,000 mcg twice weekly, or 2 mg once weekly | Practitioner protocols | Practitioner protocol (not a clinical trial) |
| CJC-1295 (form not stated): 200 mcg–1 mg on a 5 days on, 2 off pattern; 1–2 mg once or twice weekly; 2–3 mg per week. Sources vary. | Practitioner protocols | Practitioner protocol (not a clinical trial) |
| Ipamorelin 100–200 mcg at night, paired with CJC-1295 (no DAC) 200 mcg; CJC-1295 1 mg weekly also mentioned | Dr. Trevor reports | Practitioner report (not a clinical trial) |
| No dose from a human trial of the pair | Human trial (published study) | No human-trial evidence found in the PeptideWhiz study library |
Amounts are shown as each source reports them. Where sources disagree, the table lists each one; there is no single agreed amount.
Published human trials
No human-trial evidence found in the PeptideWhiz study library for CJC-1295 / Ipamorelin. The amounts above come from practitioner protocols and Dr. Trevor reports only, so the evidence level is low. See the CJC-1295 / Ipamorelin research overview for the studies we index.
FAQ
What CJC-1295 / Ipamorelin dosage is reported in research?
Reported in research: ipamorelin 100–300 mcg daily and CJC-1295 (no DAC) 100–300 mcg daily in practitioner protocols; CJC-1295 with DAC is listed at 300–1,000 mcg twice weekly or 2 mg weekly. No human-trial dose for the pair is reported in our study library. Sources vary.
Is there human-trial evidence for CJC-1295 / Ipamorelin dosing?
No. No human-trial evidence found in the PeptideWhiz study library for CJC-1295 / Ipamorelin; the amounts listed come from practitioner protocols and Dr. Trevor reports.
Why do the reported CJC-1295 / Ipamorelin amounts differ?
Each source studied or described a different group, form, goal and time frame, so reported amounts vary between sources. PeptideWhiz lists each one with its source type instead of picking a single amount.
Where can I convert a CJC-1295 / Ipamorelin amount into syringe units?
The PeptideWhiz calculator for CJC-1295 / Ipamorelin converts a vial amount, water volume and target amount into mL and syringe units. It does not suggest an amount.
Last updated: November 2, 2026.
Research information only. This page lists amounts as reported in published studies, practitioner protocols and Dr. Trevor reports. It is not medical advice and not a recommendation for any person. Sources vary, and most of these compounds are not approved for the uses discussed.